Strata Critical Medical Inc
SRTA1 位超级投资者持有。
SEC 10-K · 基本面
生意质量
截至 2025-12-31- 营收增速
- -20.7%
- 净利率
- 21.0%
- ROE
- 14.8%
- FCF 利润率
- -29.7%
估值 · 价值带
估值
缺少可用市场价格，因此不把现价放进价值带位置条。
方法与数字
所示年度的回购大体只抵消了股权激励（SBC）造成的稀释 — 应视为维持股本、而非净额回馈股东。
模型警示
- 资本开支两年翻倍：维持性 CapEx 下限后按 D&A 封顶（OE 可能偏乐观）；Greenwald 增长价值已关闭 — 成长只留在所有者盈利 DCF。
保守内在价值带（零增长底到增速封顶的 DCF）加一道有形资产地板 — 非投资建议、非买卖信号、亦非目标价。
· 重置 $1.75
护城河 低于资产基础.
Graham earnings-power value (normalized NOPAT)
Normalized operating earnings net of maintenance capex are non-positive over the years shown; earnings power cannot be capitalized.
Normalized NOPAT = average operating margin over the years shown × latest-year revenue × (1 − normalized tax); then + D&A − maintenance capex (write A). Unlevered (pre-interest, attributable to all capital). Capitalized at the 9–11% rate band (read as a WACC proxy). Enterprise → equity bridge applied: + cash − total debt.
年份：2025, 2024, 2023, 2022
v1 简化：Maintenance capex (degraded) deducted in full cash (write A): EPV = (NOPAT + D&A − maintenance capex) / WACC; no tax shield on the capex term. Maintenance-capex methods diverge by 116% (> 50%); estimate is degraded. Capex doubled within two years (AI-hog rule): flagged; the spike is treated as growth, not maintenance — owner earnings carry extra uncertainty. Share-based compensation is left as a real expense (not added back).
Buffett owner-earnings value
Normalized owner earnings are non-positive over the years shown; earnings power cannot be capitalized.
Owner earnings = average net income + average D&A − maintenance capex (zero-growth floor; no ΔNWC). Levered (starts from net income, already after interest — an equity-holder stream). Capitalized at the 9–11% rate band (read as a cost-of-equity proxy). No enterprise→equity bridge: the capitalized result is already equity value (subtracting debt would double-count interest).
年份：2025, 2024, 2023, 2022
v1 简化：Owner earnings = net income + D&A − maintenance capex (degraded); the working-capital change is excluded (maintenance ΔNWC ≈ 0; growth ΔNWC is carried in growth value, not double-counted). Maintenance-capex methods diverge by 116% (> 50%); estimate is degraded. Capex doubled within two years (AI-hog rule): flagged; the spike is treated as growth, not maintenance — owner earnings carry extra uncertainty. One-time items are not separately normalized (multi-year averaging smooths them partially). Share-based compensation is left as a real expense (not added back); see the SBC/OE disclosure. Capitalized at the 9–11% band as a cost-of-equity proxy; no leverage premium applied. Net debt or owner earnings is unavailable, so no adjustment is made.
重置价值 = 有形净资产 $143.36M = $1.75 / 股. Tangible net assets = shareholders' equity − goodwill − intangibles, ÷ diluted shares (no R&D history to capitalize).
护城河读数：Franchise test compares earnings power (EPV) against reproduction value on both AV_conservative (tangible + capitalized R&D) and AV_reproduction (conservative + acquired-reset proxy). Both must clear the franchise multiple for a moat signal; near it, a commodity; below it, value destruction. A directional reading, not a verdict.
增长价值被闸至零 — 资本开支两年翻倍（AI-hog），成长只留在所有者盈利 DCF，避免双重计入。
窗口 FY 2025, 2024, 2023, 2022 · 贴现带 9%–11% · 正常化税率 2% (Average effective tax rate over 4 year(s), capped at the statutory 21%.) · 股数 diluted.
SEC 13F · 持有人
持有该证券的超级投资者
1 位持有 · 合计 $20.9M · 本季 +0 新建 / -0 清仓
- 市值$20.9M权重（上季→本季）0.3% → 1.0% ▲
SEC 13F · 说明
文字说明
文字说明
Strata Critical Medical Inc（SRTA）被 Compounder 追踪的 1 位超级投资者持有，合计申报市值 $20.9M。仓位最大的是 Daniel Loeb，占其组合 1.0%。
以上持有人数与市值来自最新的 SEC Form 13F 申报，截至 2026-03-31 季度。来源：SEC EDGAR。13F 仅涵盖美股多头持仓，且可能滞后实际组合最多 45 天，因此这是已披露的多头持有情况，并非完整全貌。
SEC 13F · 共持信号
他们还共同持有
持有 Strata Critical Medical Inc（SRTA）的这些人还共同重仓 →
看哪些股票相对价值带便宜。 浏览全部可估值股票
数据来源· SEC EDGAR 13F 截至 2026-03-31 · 2026-05-15 提交
仅供教育与信息参考，不构成投资建议。13F 持仓为机构自行申报，可能滞后最多 45 天。
订阅更新
新一季 13F 异动与估值更新，发到你的邮箱。